Equities

Gensight Biologics SA

Gensight Biologics SA

Actions
  • Price (EUR)0.3345
  • Today's Change0.035 / 11.69%
  • Shares traded300.00
  • 1 Year change-43.88%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2.131144
Total Receivables, Net2.443.634.63
Total Inventory------
Prepaid expenses1.958.484.37
Other current assets, total0.000.220.08
Total current assets6.532353
Property, plant & equipment, net2.032.272.55
Goodwill, net------
Intangibles, net0.080.090.11
Long term investments0.500.630.62
Note receivable - long term------
Other long term assets0.000.00--
Total assets9.132657
LIABILITIES
Accounts payable5.637.8112
Accrued expenses1.813.642.48
Notes payable/short-term debt000
Current portion long-term debt/capital leases172.435.41
Other current liabilities, total0.460.762.80
Total current liabilities251522
Total long term debt6.161512
Total debt241818
Deferred income tax------
Minority interest------
Other liabilities, total8.39116.32
Total liabilities404141
SHAREHOLDERS EQUITY
Common stock1.631.161.16
Additional paid-in capital191181181
Retained earnings (accumulated deficit)(223)(198)(166)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.000.000.00
Total equity(31)(15)16
Total liabilities & shareholders' equity9.132657
Total common shares outstanding654646
Treasury shares - common primary issue0.3400
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.